Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa | Zendy

Yulin Zhang | Zendy; Jiankang Zhao | Zendy; Jiajing Han | Zendy; Yanyan Fan | Zendy; Zhujia Xiong | Zendy; Xiaohui Zou | Zendy; Binbin Li | Zendy; Xinmeng Liu | Zendy; Ziyao Li | Zendy; Binghuai Lu | Zendy; Bin Cao | Zendy

Open Access

Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa

Author(s) -

Yulin Zhang,

Jiankang Zhao,

Jiajing Han,

Yanyan Fan,

Zhujia Xiong,

Xiaohui Zou,

Binbin Li,

Xinmeng Liu,

Ziyao Li,

Binghuai Lu,

Bin Cao

Publication year - 2022

Publication title -

microbiology spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.502

H-Index - 51

ISSN - 2165-0497

DOI - 10.1128/spectrum.02740-21

Subject(s) - ceftazidime/avibactam , avibactam , microbiology and biotechnology , ceftazidime , pseudomonas aeruginosa , drug resistance , biology , antimicrobial , efflux , bacteria , genetics

Handling the infections by extensively drug-resistantPseudomonas aeruginosa (XDRPA) strains is challenging due to their complicated antibiotic resistance mechanisms in immunosuppressed patients with pulmonary diseases (e.g., cystic fibrosis, chronic obstructive pulmonary disease, and lung transplant), ventilator-associated pneumonia, and bloodstream infections. The current study suggested the potentiality of the ceftazidime-avibactam-imipenem combination against XDRPA withbla AmpC overexpression or mutation, decreased OprD porin, and/or upregulated efflux pumps.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research